Literature DB >> 34801522

Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.

Linda Vanessa Márquez-Quiroga1, Jaime Arellanes-Robledo2, Verónica Rocío Vásquez-Garzón3, Saul Villa-Treviño4, Pablo Muriel5.   

Abstract

Hepatocellular carcinoma (HCC), the most common primary liver cancer, arises after a long period of exposure to etiological factors. Nonalcoholic steatohepatitis (NASH) is ranked as the main risk factor for developing HCC; hence, experimental models of NASH leading to HCC have become key tools both to investigate the molecular mechanisms underlying the pathophysiology and to evaluate new putative drugs for treating chronic liver diseases in humans. Animal models of NASH induced by a high-fat diet (HFD) plus chemical inducers, such as the NASH-HCC (STAM), high-fat diet/diethylnitrosamine (HFD/DEN), choline-deficient high-fat diet/DEN (CDHFD/DEN), and Western diet/carbon tetrachloride (WD/CCl4) models, are promising because they exacerbate liver damage and significantly shorten the experimental time. In this review, we critically summarize and discuss the ability of these models to recapitulate the liver alterations that precede and lead to HCC progression, as well as the impact of the diet in promoting liver injury progression. We also emphasize the strengths and weaknesses of the models' ability to closely mimic the stages of liver injury development that occur in humans. Based on the molecular mechanisms induced by the currently available NASH models leading to HCC, we argue that although several NASH models have importantly contributed to describing the disease chronology, the progress in emulating the progression from NASH to HCC has been partial. Thus, the development of novel NASH/HCC models remains an unmet need.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diethylnitrosamine; Hepatocellular carcinoma; High fatty diet; Non-alcoholic steatohepatitis; STAM; Western diet

Mesh:

Substances:

Year:  2021        PMID: 34801522     DOI: 10.1016/j.bcp.2021.114845

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.

Authors:  Meixi Wang; Jianrui Li; Hu Li; Biao Dong; Jing Jiang; Nannan Liu; Jiali Tan; Xuekai Wang; Lei Lei; Hongying Li; Han Sun; Mei Tang; Huiqiang Wang; Haiyan Yan; Yuhuan Li; Jiandong Jiang; Zonggen Peng
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  The Critical and Diverse Roles of CD4-CD8- Double Negative T Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Changying Li; Xiaonan Du; Zongshan Shen; Yunxiong Wei; Yaning Wang; Xiaotong Han; Hua Jin; Chunpan Zhang; Mengyi Li; Zhongtao Zhang; Songlin Wang; Dong Zhang; Guangyong Sun
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2022-03-02

Review 3.  Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.

Authors:  Tingyu Fang; Hua Wang; Xiaoyue Pan; Peter J Little; Suowen Xu; Jianping Weng
Journal:  Int J Biol Sci       Date:  2022-09-06       Impact factor: 10.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.